Document is current
Any future updates will be listed below
-
Authors
Vesperinas, Ana https://orcid.org/0000-0003-1919-9382
Rocaspana-Codana, Josep
Reyes-Leiva, David
Caballero-Ávila, Marta
Carbayo, Álvaro
Collet-Vidiella, Roger
Llansó, Laura
Gallardo, Eduard
Turon-Sans, Joana
Rojas-García, Ricard
Cortés-Vicente, Elena
-
Funding
Funding for this research was provided by:
Argenx
- License Information
-
More Information
Article History
Received: 3 February 2026
Accepted: 25 March 2026
First Online: 9 April 2026
Declarations
:
: Ana Vesperinas has received public speaking honoraria and compensation for advisory boards and consultation fees from argenx, UCB, Bial and Alexion. Elena Cortés-Vicente has received public speaking honoraria and compensation for advisory boards and consultation fees from UCB, argenx, Alexion, Johnson and Johnson, Amgen and Lundbeck. Josep Rocaspana-Codana, David Reyes-Leiva, Marta Caballero-Ávila, Alvaro Carbayo, Roger Collet-Vidiella, Laura Llansó, Eduard Gallardo, Joana Turon-Sans and Ricard Rojas-García have nothing to disclose.
: This study was conducted in accordance with the principles of the Declaration of Helsinki (1964) and its subsequent amendments and has been approved by the Ethics Committee of the Hospital de la Santa Creu i Sant Pau (code IIBSP-MIA-2023–03). All participants signed an informed consent for participation in the study and for the publication of anonymized data prior to their inclusion. The myMGverse APP is a medical device with CE marking in accordance with the Medical Devices Directive (MDD, 93/42/EEC).
